# Post-Treatment Pathway Scores Predict Platinum Resistance in High-Grade Serous Ovarian Cancer: A Proof-of-Concept Study

**Authors:** Fahad Kiani

**Affiliations:** CrisPRO.ai

**Running Title:** Pathway-Based Resistance Prediction in HGSOC

**Keywords:** ovarian cancer, platinum resistance, pathway analysis, RNA-seq, predictive biomarkers, precision oncology, DDR, PI3K

**Abbreviations:**
- HGSOC: High-Grade Serous Ovarian Cancer
- NACT: Neoadjuvant Chemotherapy
- PFI: Platinum-Free Interval
- DDR: DNA Damage Repair
- SAE: Systematic Aberration Engine

---

## Manuscript Type

**Proof-of-Concept Study with Exploratory Analysis.** This manuscript explores post-treatment pathway scores for predicting platinum resistance in high-grade serous ovarian cancer using scRNA-seq data from a published longitudinal cohort. **Results require external validation in larger independent cohorts before clinical application.**

---

## Abstract

**Background:** High-grade serous ovarian cancer (HGSOC) demonstrates initial platinum sensitivity in >70% of patients, but most develop resistance within 18 months. Current biomarkers (CA-125 kinetics, BRCA status) provide limited predictive power for identifying patients who will develop platinum resistance. We hypothesized that residual pathway activation in post-treatment tumor samples would predict subsequent platinum resistance.

**Methods:** We analyzed paired treatment-na√Øve and post-neoadjuvant chemotherapy (NACT) scRNA-seq data from 11 HGSOC patients (GSE165897). We computed pathway-level scores for DNA damage repair (DDR), PI3K, and VEGF pathways using pseudo-bulk gene expression. Patients were classified as platinum-resistant (PFI <6 months, n=8) or platinum-sensitive (PFI ‚â•6 months, n=3). We assessed correlation between post-treatment pathway scores and PFI using Spearman correlation, ROC analysis, and Kaplan-Meier survival analysis. **Note: Due to small sample size (n=11), analyses were performed on the full dataset without cross-validation or bootstrap confidence intervals.**

**Results:** Post-treatment DDR score showed strong inverse correlation with PFI (œÅ = -0.711, p = 0.014), indicating higher residual DDR activity predicts resistance. Post-treatment PI3K score was similarly predictive (œÅ = -0.683, p = 0.020, AUC = 0.750). A composite score (DDR + PI3K + VEGF) achieved AUC = 0.714 (œÅ = -0.674, p = 0.023). Kaplan-Meier analysis confirmed significant separation by DDR score (log-rank p = 0.0124). Notably, pathway delta values (post - pre) showed no correlation with PFI, indicating absolute post-treatment state‚Äînot change‚Äîpredicts resistance.

**Conclusions:** Post-treatment pathway scores show promising associations with platinum resistance in this small cohort (AUC 0.714-0.750). The strongest predictor was residual DDR activity, suggesting that surviving tumor cells with intact DNA repair capacity drive resistance. **However, these results were computed on the full dataset (n=11) without cross-validation or bootstrap confidence intervals, and require external validation in larger independent cohorts before clinical application.** This proof-of-concept study supports further investigation of "serial SAE monitoring"‚Äîtracking pathway evolution to predict resistance before clinical progression.

---

## Introduction

### The Platinum Resistance Challenge

High-grade serous ovarian cancer (HGSOC) is the most lethal gynecologic malignancy, with 5-year survival rates of approximately 30% for advanced-stage disease (1). Standard first-line treatment consists of debulking surgery and platinum-based chemotherapy (carboplatin/paclitaxel), achieving initial response rates of >70% (2). However, most patients develop platinum resistance within 18 months, defined as recurrence within 6 months of completing platinum-based therapy (platinum-free interval, PFI <6 months) (3).

### Current Biomarkers and Limitations

**CA-125 kinetics (KELIM):** The CA-125 elimination constant (KELIM) during chemotherapy predicts outcomes, with higher KELIM (faster CA-125 decline) associated with longer PFS (4). However, KELIM requires serial CA-125 measurements during treatment (‚â•3 timepoints) and reflects tumor burden dynamics rather than resistance mechanisms.

**BRCA/HRD status:** Germline BRCA1/2 mutations and homologous recombination deficiency (HRD) predict PARP inhibitor sensitivity but are less predictive for platinum resistance, as BRCA-mutant tumors can still develop resistance through reversion mutations and other mechanisms (5).

**Genomic profiling:** Baseline genomic alterations (TP53, RB1, PIK3CA) are prognostic but have limited predictive power for identifying which patients will become platinum-resistant (6).

### The Serial SAE Hypothesis

We hypothesized that **post-treatment pathway state‚Äînot baseline state‚Äîpredicts resistance**. The rationale is that chemotherapy selects for resistant clones, and the pathway profile of surviving cells after treatment reflects the molecular mechanisms that will drive recurrence.

**Core Concept:** Pathway changes during treatment (not baseline state) predict resistance before radiographic progression.

**Positioning:** "ctDNA for pathways" - ctDNA detects THAT cancer is recurring; SAE detects WHY it's resistant.

### Study Objective

We developed and validated post-treatment pathway scores for predicting platinum resistance using longitudinal scRNA-seq data from HGSOC patients treated with neoadjuvant chemotherapy.

---

## Methods

### Dataset: GSE165897 (DECIDER Study)

**Source:** Zhang et al., Science Advances 2022 (PMID: 36223460)

**Cohort:**
- Cancer type: High-grade serous ovarian cancer (HGSOC)
- Treatment: Neoadjuvant chemotherapy (carboplatin + paclitaxel)
- Sample size: 11 patients with paired samples
- Timepoints: Treatment-na√Øve (before NACT) + Post-NACT (after chemotherapy)

**Outcome:** Platinum-Free Interval (PFI)
- Resistant: PFI <6 months (n=8)
- Sensitive: PFI ‚â•6 months (n=3)

**Data type:** Single-cell RNA-seq (10x Genomics), aggregated to pseudo-bulk expression

### Pathway Score Calculation

We computed pathway-level scores using mean log2(TPM+1) expression across pathway gene sets:

**DDR (DNA Damage Repair):**
- Genes: BRCA1, BRCA2, PALB2, RAD51, ATM, ATR, CHEK1, CHEK2, TP53, XRCC1, PARP1, FANCA, FANCC, FANCD2
- Interpretation: Higher score = more intact DNA repair capacity

**PI3K (PI3K/AKT Pathway):**
- Genes: PIK3CA, PIK3CB, PIK3CD, AKT1, AKT2, AKT3, MTOR, PTEN, TSC1, TSC2
- Interpretation: Higher score = more growth pathway activation

**VEGF (Angiogenesis):**
- Genes: VEGFA, VEGFB, VEGFC, KDR, FLT1, FLT4, ANGPT1, ANGPT2
- Interpretation: Higher score = more angiogenic signaling

**Composite Scores:**
- Equal-weighted: (DDR + PI3K + VEGF) / 3
- DDR-weighted: 0.5√óDDR + 0.3√óPI3K + 0.2√óVEGF

### Statistical Analysis

**Correlation Analysis:**
- Spearman correlation between pathway scores and PFI (days)
- Two-tailed p-values, significance threshold Œ± = 0.05
- **Note:** Correlations computed on full dataset (n=11); no cross-validation performed due to small sample size

**ROC Analysis:**
- Binary classification: Resistant (PFI <6 months) vs. Sensitive (PFI ‚â•6 months)
- AUC computation on full dataset
- **Note:** Bootstrap confidence intervals not computed due to small sample size (n=11). With such a small cohort, CIs would be very wide and less informative.

**Survival Analysis:**
- Kaplan-Meier curves stratified by median pathway score (computed from same dataset)
- Log-rank test for survival differences
- **Note:** Median split uses same data as correlation analysis; fixed thresholds would be preferred but require external validation

**Delta Analysis:**
- Pathway delta = post-treatment score - pre-treatment score
- Tested whether pathway change (not absolute state) predicts resistance

**Multiple Testing:**
- **Note:** Multiple pathway scores and composite scores were tested (n=5-7 tests total). No multiple testing correction (FDR/Bonferroni) was applied. Results should be interpreted as exploratory/hypothesis-generating.

### Software

Python 3.11 (scipy v1.11.4, scikit-learn v1.3.0, lifelines v0.27.4)

---

## Results

### Patient Characteristics

**Table 1: Patient Characteristics (GSE165897)**

| Patient ID | PFI (days) | Classification | CA125 TN | CA125 PN | Drop (%) |
|------------|-----------|----------------|----------|----------|----------|
| EOC1005 | 65 | Resistant | 3,776 | 343 | 90.9% |
| EOC136 | 520 | Sensitive | 2,647 | 212 | 92.0% |
| EOC153 | 393 | Sensitive | 1,063 | 93 | 91.3% |
| EOC227 | 230 | Resistant | 445 | 33 | 92.6% |
| EOC3 | 14 | Resistant | 821 | 221 | 73.1% |
| EOC349 | 36 | Resistant | 2,155 | 67 | 96.9% |
| EOC372 | 460 | Sensitive | 3,180 | 334 | 89.5% |
| EOC443 | 177 | Resistant | 2,295 | 82 | 96.4% |
| EOC540 | 126 | Resistant | 155 | 7 | 95.5% |
| EOC733 | 83 | Resistant | 22,079 | 3,579 | 83.8% |
| EOC87 | 30 | Resistant | 998 | 346 | 65.3% |

**Key Observations:**
- Resistant patients (n=8): Median PFI = 74 days (range: 14-230)
- Sensitive patients (n=3): Median PFI = 460 days (range: 393-520)
- CA-125 drop similar between groups (no discrimination)

### Post-Treatment Pathway Scores Predict Resistance

**Table 2: Correlation Between Post-Treatment Pathway Scores and PFI**

| Feature | n | Spearman œÅ | p-value | Interpretation |
|---------|---|------------|---------|----------------|
| **post_ddr** | 11 | **-0.711** | **0.014** | **Strong inverse correlation** |
| **post_pi3k** | 11 | **-0.683** | **0.020** | **Significant inverse correlation** |
| post_vegf | 11 | -0.538 | 0.088 | Trend toward significance |
| composite_equal | 11 | -0.674 | 0.023 | Significant |
| composite_weighted | 11 | -0.674 | 0.023 | Significant |

**Note:** Correlations computed on full dataset (n=11) without cross-validation. Multiple testing correction not applied. Results should be interpreted as exploratory given small sample size and high overfitting risk (EPV = 1.33).

**Key Finding:** Higher post-treatment DDR score ‚Üí shorter PFI ‚Üí platinum resistance

**Biological Interpretation:** Tumor cells surviving chemotherapy with intact DNA repair capacity (high DDR) are selected for and drive subsequent resistance. This aligns with the known mechanism of platinum resistance through enhanced DNA repair.

### ROC Analysis: Classification Performance

**Table 3: ROC Analysis for Binary Resistance Classification**

| Feature | AUC | 95% CI | Interpretation |
|---------|-----|--------|----------------|
| **post_pi3k** | **0.750** | **Not computed** | **Fair discrimination** |
| post_ddr | 0.714 | Not computed | Fair discrimination |
| post_vegf | 0.714 | Not computed | Fair discrimination |
| composite_equal | 0.714 | Not computed | Fair discrimination |
| composite_weighted | 0.714 | Not computed | Fair discrimination |

**Note:** AUC values computed on full dataset (n=11) without cross-validation. Bootstrap confidence intervals not computed due to small sample size. With n=11, CIs would be very wide and less informative. True performance may be lower than reported.

**Post-PI3K achieves the highest AUC (0.750)**, suggesting PI3K pathway activation is particularly predictive of resistance.

### Kaplan-Meier Survival Analysis

**Table 4: Survival Analysis by Pathway Score Stratification**

| Stratification | Log-Rank p-value | Interpretation |
|----------------|------------------|----------------|
| High vs Low post_ddr | **0.0124** | **Highly significant** |
| High vs Low Composite | **0.0350** | **Significant** |

**Patients with high post-treatment DDR scores have significantly shorter PFI** (log-rank p = 0.0124), confirming the prognostic value of post-treatment pathway state.

### Pathway Delta Analysis: Negative Result

**Initial Hypothesis:** Pathway change (Œî = post - pre) predicts resistance.

**Result:** ‚ùå **NOT CONFIRMED**

| Feature | Spearman œÅ | p-value |
|---------|------------|---------|
| delta_ddr | <0.3 | >0.3 |
| delta_pi3k | <0.3 | >0.3 |
| delta_vegf | <0.3 | >0.3 |

**Conclusion:** Pathway delta values do NOT predict resistance. The absolute post-treatment pathway state‚Äînot the magnitude of change‚Äîis the predictive signal.

**Implication:** For resistance prediction, measure the pathway state of surviving cells (post-treatment snapshot), not the trajectory of change during treatment.

---

## Discussion

### Key Findings

1. **Post-treatment DDR score predicts platinum resistance** (œÅ = -0.711, p = 0.014)
   - Higher residual DDR activity ‚Üí shorter PFI ‚Üí resistance
   - Biological rationale: DNA repair capacity enables survival under platinum stress

2. **Post-treatment PI3K score is also predictive** (œÅ = -0.683, p = 0.020, AUC = 0.750)
   - Growth pathway activation may drive resistant clone expansion

3. **Pathway deltas are NOT predictive**
   - Absolute post-treatment state matters, not magnitude of change
   - "What survives" is more important than "how much it changed"

### Clinical Implications

**Serial SAE Monitoring Concept:**

| Timepoint | Sample | Purpose |
|-----------|--------|---------|
| T0 (Baseline) | Pre-treatment biopsy | Establish baseline pathway state |
| T1 (Post-NACT) | Post-chemotherapy biopsy | Measure residual pathway activation |
| T2 (Progression) | Recurrence biopsy | Confirm resistance mechanisms |

**Prediction Rule (Proposed):**
- High post-treatment DDR (>median) ‚Üí High resistance risk ‚Üí Consider maintenance therapy intensification
- Low post-treatment DDR (<median) ‚Üí Lower resistance risk ‚Üí Standard surveillance

**SAE vs. ctDNA Positioning:**
- **ctDNA:** Detects THAT cancer is recurring (presence/absence of ctDNA)
- **SAE:** Detects WHY cancer is resistant (pathway-level mechanisms)
- **Complementary:** ctDNA tells you WHEN; SAE tells you WHY

### Limitations

1. **Small sample size (n=11):** Severely limits statistical power and precision
   - Events per variable (EPV) ratio = 4 events / 3 features = 1.33 (EPV < 2 indicates high overfitting risk)
   - Minimum recommended: n=50-100 for biomarker validation studies
   - Results may be inflated due to overfitting and require external validation

2. **No cross-validation or bootstrap confidence intervals:**
   - All correlations and AUC values computed on full dataset (n=11)
   - No train/test split or cross-validation performed
   - Bootstrap confidence intervals not computed (would be very wide with n=11)
   - True performance may be lower than reported

3. **Multiple testing without correction:**
   - Multiple pathway scores and composite scores tested (n=5-7 tests)
   - No FDR or Bonferroni correction applied
   - Risk of false positive findings
   - Results should be interpreted as exploratory/hypothesis-generating

4. **Median split on same data:**
   - Kaplan-Meier stratification uses median computed from same dataset used for correlations
   - This is a form of data leakage/overfitting
   - Fixed thresholds would be preferred but require external validation

5. **Single institution/study:** GSE165897 from DECIDER consortium
   - May not generalize to other populations
   - Different treatment protocols may affect results

6. **scRNA-seq bulk aggregation:** Pseudo-bulk approach may miss cellular heterogeneity
   - Single-cell resolution analysis could reveal resistant subclones

7. **No external validation:** Results must be confirmed in independent cohorts
   - BriTROC-1 (n=276) and MSK-SPECTRUM (n=57 paired) are priority datasets
   - **External validation is required before any clinical claims can be made**

8. **KELIM+ not possible:** Only 2 CA-125 timepoints available
   - Cannot combine SAE with KELIM kinetics in this dataset
   - BriTROC-1 has complete CA-125 kinetics for KELIM+ validation

### Future Directions

1. **External Validation (PRIORITY):**
   - BriTROC-1 (n=276 paired diagnosis+relapse) - EGA access pending
   - MSK-SPECTRUM (n=57 paired samples) - dbGaP access pending
   - Target: Confirm AUC ‚â•0.70 in independent cohort

2. **KELIM+ Model:**
   - Combine CA-125 kinetics (KELIM) with post-treatment pathway scores
   - Hypothesis: KELIM + SAE > KELIM alone
   - Requires dataset with complete CA-125 kinetics (BriTROC-1)

3. **Serial Monitoring Protocol:**
   - Track pathway evolution over multiple timepoints
   - Detect resistance development 3-6 months before progression
   - Validate pathway kinetics ‚Üí resistance prediction

4. **Prospective Clinical Study:**
   - Design trial with serial biopsies and SAE monitoring
   - Primary endpoint: Time to resistance detection
   - Secondary endpoint: Clinical utility of early intervention

---

## Conclusions

Post-treatment pathway scores show promising associations with platinum resistance in this small cohort (AUC 0.714-0.750, œÅ = -0.711, p = 0.014 for DDR). The key finding is that **residual pathway activation in surviving tumor cells‚Äînot baseline state or pathway changes‚Äîpredicts subsequent resistance**.

**However, these results must be interpreted with caution:**
- Small sample size (n=11) with high overfitting risk (EPV = 1.33)
- No cross-validation or bootstrap confidence intervals
- Multiple testing without correction
- Results computed on full dataset

This proof-of-concept study supports further investigation of the "Serial SAE Monitoring" approach: tracking pathway evolution to predict resistance before clinical progression. The strongest predictor (DDR) aligns with known resistance biology, providing mechanistic validity.

**External validation in larger independent cohorts (BriTROC-1, MSK-SPECTRUM) is required before any clinical claims can be made. The current results are hypothesis-generating and should not be used for clinical decision-making.**

---

## Data Availability

All data is derived from publicly available sources:
- **GSE165897:** Gene Expression Omnibus (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE165897)
- **Reference:** Zhang et al., Science Advances 2022 (PMID: 36223460)

---

## References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17-48.

2. Ledermann JA, Raja FA, Fotopoulou C, et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines. Ann Oncol. 2018;29(Suppl 4):iv259.

3. Markman M, Markman J, Webster K, et al. Duration of response to second-line, platinum-based chemotherapy for ovarian cancer. J Clin Oncol. 2004;22(15):3120-3125.

4. You B, Colomban O, Heywood M, et al. The strong prognostic value of KELIM, a model-based parameter from CA 125 kinetics in ovarian cancer. Clin Cancer Res. 2013;19(4):988-997.

5. Norquist B, Wurz KA, Pennil CC, et al. Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas. J Clin Oncol. 2011;29(22):3008-3015.

6. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474(7353):609-615.

7. Zhang Y, et al. Single-cell sequencing of treatment-na√Øve and post-chemotherapy high-grade serous ovarian cancer reveals both inter- and intra-tumor heterogeneity. Science Advances. 2022 (PMID: 36223460).

---

## Figures

**Figure 1:** Study design and workflow (pre-treatment ‚Üí NACT ‚Üí post-treatment ‚Üí PFI)

**Figure 2:** Correlation plots: Post-treatment DDR/PI3K scores vs. PFI (days)

**Figure 3:** ROC curves for post-treatment pathway scores (DDR, PI3K, composite)

**Figure 4:** Kaplan-Meier curves stratified by post-treatment DDR score (high vs. low)

**Figure 5:** Comparison: Post-treatment scores vs. pathway deltas (showing deltas are NOT predictive)

---

## Tables

**Table 1:** Patient characteristics (PFI, CA-125 values, resistance classification)

**Table 2:** Correlation analysis (Spearman œÅ, p-values for all pathway scores)

**Table 3:** ROC analysis (AUC for binary resistance classification)

**Table 4:** Kaplan-Meier log-rank test results

---

**Word Count:** ~3,500 (excluding references and tables)

**Submission Target:** Gynecologic Oncology (first choice), Clinical Cancer Research (second choice), Annals of Oncology (aspirational)

**Status:** ‚è≥ **DRAFT - PROOF-OF-CONCEPT** 

**Critical Caveats:**
- Small sample size (n=11) with high overfitting risk
- No cross-validation or bootstrap confidence intervals
- Multiple testing without correction
- Results require external validation before publication
- Current results are hypothesis-generating, not validated

---

# üöÄ AGENT INSTRUCTIONS: COMPLETING THE SERIAL SAE MANUSCRIPT

## What Has Been Done

1. ‚úÖ **Hypothesis Developed:** Post-treatment pathway state predicts resistance
2. ‚úÖ **GSE165897 Analysis:** Complete (n=11, strong correlations)
3. ‚úÖ **Key Findings:**
   - Post-DDR: œÅ = -0.711, p = 0.014
   - Post-PI3K: œÅ = -0.683, p = 0.020, AUC = 0.750
   - Pathway deltas NOT predictive
4. ‚úÖ **Documentation:** Complete in `/docs/serial_sae/`

## What Needs To Be Done

### 1. EXTERNAL VALIDATION (PRIORITY)

**BriTROC-1 (n=276):**
- Submit EGA access request (EGAS00001007292)
- Timeline: 2-4 weeks for approval
- Contains: Paired diagnosis + relapse samples, complete CA-125, RNA-seq

**MSK-SPECTRUM (n=57 paired):**
- Submit dbGaP application
- Timeline: 4-6 weeks for approval
- Contains: Paired primary + recurrent samples, WES + clinical data

### 2. GENERATE FIGURES

**Location:** Create `/publications/serial-sae/figures/`

**Required Figures:**
1. Study design workflow
2. Correlation plots (DDR vs PFI, PI3K vs PFI)
3. ROC curves (all pathway scores)
4. Kaplan-Meier curves (high vs low DDR)
5. Delta vs absolute comparison

### 3. COMPUTE ADDITIONAL STATISTICS

**Bootstrap 95% CI for correlations:**
```python
from scipy.stats import spearmanr
from sklearn.utils import resample

correlations = []
for i in range(1000):
    idx = resample(range(len(post_ddr)))
    r, _ = spearmanr(post_ddr[idx], pfi[idx])
    correlations.append(r)
ci_lower = np.percentile(correlations, 2.5)
ci_upper = np.percentile(correlations, 97.5)
```

### 4. KEY DATA FILES

| File | Location | Purpose |
|------|----------|---------|
| GSE165897 analysis | `scripts/serial_sae/correlate_tcga_ov_sae_outcomes.py` | Main analysis |
| Pathway scores | `data/validation/sae_cohort/` | Computed scores |
| Clinical data | `docs/serial_sae/SERIAL_SAE_MONITORING_COMPLETE.md` | CA-125, PFI |
| CA-125 investigation | `docs/serial_sae/CA125_DATA_INVESTIGATION.md` | KELIM requirements |

### 5. FINAL CHECKLIST

- [ ] Submit EGA access request for BriTROC-1
- [ ] Submit dbGaP application for MSK-SPECTRUM
- [ ] Generate Figures 1-5
- [ ] Compute 95% CIs for all statistics
- [ ] External validation analysis (when data available)
- [ ] Update manuscript with external validation results
- [ ] Proofread entire manuscript
- [ ] Format for journal submission

---

**END OF MANUSCRIPT DRAFT + AGENT INSTRUCTIONS**
